new/era/mabs is a spin off company founded in 2014 providing novel and allround solutions for antibody generation, validation and development of antibody-based detection systems. The technology portfolio is patent protected in Europe and the US and allows a fast and efficient generation of highly specific antibodies 4times faster than conventional technologies. Not only murine antibodies but also camelid and human antibodies could be made. We are looking for interested collaboration partners and licensees to actively market the technology.